epinastine has been researched along with Rhinitis, Allergic, Seasonal in 8 studies
epinastine: RN given refers parent cpd
epinastine : A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.
Rhinitis, Allergic, Seasonal: Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 9.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 9.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| "The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allergic conjunctivitis (SAC) exposed to environmental allergens." | 9.11 | Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. ( Abelson, MB; Bradford, R; Lue, J; Schiffman, RM; Whitcup, SM, 2004) |
| "The aim of this study was to assess the efficacy and tolerability of topically administered ophthalmic epinastine using the conjunctival antigen challenge (CAC) model in patients with a history of allergic conjunctivitis." | 9.11 | Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. ( Abelson, MB; Bradford, RR; Crampton, HJ; Gomes, P; Schiffman, RM; Whitcup, SM, 2004) |
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 5.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 5.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| "The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allergic conjunctivitis (SAC) exposed to environmental allergens." | 5.11 | Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. ( Abelson, MB; Bradford, R; Lue, J; Schiffman, RM; Whitcup, SM, 2004) |
| "The aim of this study was to assess the efficacy and tolerability of topically administered ophthalmic epinastine using the conjunctival antigen challenge (CAC) model in patients with a history of allergic conjunctivitis." | 5.11 | Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. ( Abelson, MB; Bradford, RR; Crampton, HJ; Gomes, P; Schiffman, RM; Whitcup, SM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujishima, H | 1 |
| Ohashi, Y | 1 |
| Takamura, E | 1 |
| Izumi, N | 1 |
| Mizuguchi, H | 1 |
| Umehara, H | 1 |
| Ogino, S | 1 |
| Fukui, H | 1 |
| Gotoh, M | 1 |
| Hashiguchi, K | 1 |
| Okubo, K | 1 |
| Suzuki, Y | 1 |
| Inoue, T | 1 |
| Yamamoto, A | 1 |
| Sugimoto, Y | 1 |
| Whitcup, SM | 2 |
| Bradford, R | 1 |
| Lue, J | 1 |
| Schiffman, RM | 2 |
| Abelson, MB | 2 |
| Gomes, P | 1 |
| Crampton, HJ | 1 |
| Bradford, RR | 1 |
| Ohmura, T | 1 |
| Kawasaki, T | 1 |
| Ousler, GW | 1 |
| Workman, DA | 1 |
| Torkildsen, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -[NCT01363700] | Phase 3 | 87 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.4 |
| Olopatadine Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 3.7 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores. Count unit was defined each eye.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 4.1 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.2 |
| Olopatadine Ophthalmic Solution | 0.2 |
| Placebo Ophthalmic Solution | 1.5 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge and graded on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch. Count unit was defined each eye.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.4 |
| Placebo Ophthalmic Solution | 1.7 |
1 review available for epinastine and Rhinitis, Allergic, Seasonal
| Article | Year |
|---|---|
[Pharmacological and clinical profile of epinastine hydrochloride (Alesion Dry Syrup 1%)].
Topics: Animals; Child, Preschool; Dermatitis, Atopic; Dibenzazepines; Histamine H1 Antagonists; Humans; Imi | 2006 |
[Pharmacological and clinical profile of epinastine hydrochloride (Alesion Dry Syrup 1%)].
Topics: Animals; Child, Preschool; Dermatitis, Atopic; Dibenzazepines; Histamine H1 Antagonists; Humans; Imi | 2006 |
5 trials available for epinastine and Rhinitis, Allergic, Seasonal
| Article | Year |
|---|---|
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Cedrus; Conjunctiva; Conjunctivitis, Allergic; Dibenzazepine | 2014 |
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Cedrus; Conjunctiva; Conjunctivitis, Allergic; Dibenzazepine | 2014 |
Efficacy of epinastine hydrochloride for antigen-provoked nasal symptoms in subjects with orchard grass pollinosis.
Topics: Adult; Allergens; Anti-Allergic Agents; Cross-Over Studies; Dactylis; Dibenzazepines; Double-Blind M | 2011 |
Efficacy of epinastine hydrochloride for antigen-provoked nasal symptoms in subjects with orchard grass pollinosis.
Topics: Adult; Allergens; Anti-Allergic Agents; Cross-Over Studies; Dactylis; Dibenzazepines; Double-Blind M | 2011 |
Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazep | 2007 |
An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazep | 2007 |
2 other studies available for epinastine and Rhinitis, Allergic, Seasonal
| Article | Year |
|---|---|
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice.
Topics: Animals; Anti-Allergic Agents; Behavior, Animal; Benzoquinones; Carbazoles; Dibenzazepines; Disease | 2011 |
Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice.
Topics: Animals; Anti-Allergic Agents; Behavior, Animal; Benzoquinones; Carbazoles; Dibenzazepines; Disease | 2011 |